Survodutide reduces mean body weight by 12.2% or 13.0% in adults with obesityTrial shows survodutide helps adults lose weight over 76 weeks

This Phase 3 randomized controlled trial investigated the efficacy and safety of survodutide in a population of 725 adults with obesity. Eligible participants had a BMI of 30 or higher, or a BMI of 27 or higher with at least one obesity-related complication. Notably, patients with diabetes were excluded from this study. The trial was designed to evaluate weight loss over a duration of 76 weeks.

The intervention group received survodutide administered subcutaneously once weekly. The dosage was adjusted up to 3.6 mg or 6.0 mg and accompanied by lifestyle modification counseling. The comparator group received a placebo along with the same lifestyle modification counseling. This design allowed for a direct comparison of the pharmacological impact of survodutide on body weight in patients without diabetes.

The primary outcome was the percent change in body weight and the proportion of participants achieving a reduction of at least 5% from baseline to week 76. Results showed mean percent changes in body weight of -12.2% (95% CI, -13.6 to -10.8) for one treatment group (n=241) and -13.0% (95% CI, -14.4 to -11.6) for a second treatment group (n=242). In contrast, the third group reported a mean reduction of only -5.4% (95% CI, -6.9 to -4.0; n=242). Regarding the proportion of participants achieving at least 5% weight loss, the results were 72.6%, 71.9%, and 46.3% respectively for the three groups. These findings were statistically significant with a p-value of less than 0.001 compared to placebo.

Secondary outcomes were not reported. However, the primary results clearly indicate that survodutide provides a substantial reduction in body weight compared to placebo over the 76-week period for patients meeting the inclusion criteria.

Safety and tolerability findings indicated that gastrointestinal symptoms were common among participants. Specifically, 80.9% of those in the 3.6-mg group and 89.7% of those in the 6.0-mg group experienced gastrointestinal symptoms. In the placebo group, 47.9% of participants reported similar issues. These symptoms were generally characterized as mild to moderate. No specific data regarding serious adverse events or total discontinuation rates were provided.

These results contribute to the growing evidence for GLP-1 receptor agonists in weight management. While previous studies have established the efficacy of various agents in this class, these findings specifically confirm the potency of survodutide in a non-diabetic population over a long duration of 76 weeks. The high certainty of these results is supported by the Phase 3 randomized controlled trial design.

Methodological limitations include the exclusion of patients with diabetes and the lack of reported data on serious adverse events or specific discontinuation rates. Additionally, while gastrointestinal symptoms were common, their impact on long-term adherence was not quantified in this summary.

Clinically, these results suggest that survodutide is a viable option for managing obesity in adults without diabetes. The significant difference between the 12.2% to 13.0% weight loss in treatment groups versus the 5.4% in the placebo group suggests a robust clinical effect. Questions remain regarding the long-term durability of weight loss beyond 76 weeks and the specific impact of gastrointestinal side effects on patient persistence in real-world practice.